REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

✅ VALIDAR RBR/CHECK REGISTER CODE 📊 PAINEL DE DADOS/DASHBOARD

Public trial

Effect of two therapeutic modalities on chronic hip pain

Date of registration: 09/30/2019 ^(mm/dd/yyyy)
Last approval date : 06/05/2020 ^(mm/dd/yyyy)
Last revision: 3

Study type:

Interventional

Evaluation of the prediction of soft tissues of the face with computed tomography of dental and bone deformities before and after surgery of retracted jaws

Date of registration: 06/04/2020 ^(mm/dd/yyyy)
Last approval date : 06/04/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of efficacy and efficiency of a removable esthetic appliance for solving teeth crowding in the childhood: a randomized clinical trial

Date of registration: 06/04/2020 ^(mm/dd/yyyy)
Last approval date : 06/04/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Full versus prophylactic anticoagulation for the treatment of severe forms of Covid-19:

Date of registration: 05/06/2020 ^(mm/dd/yyyy)
Last approval date : 06/04/2020 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Study of efficiency and effectiveness of a new family of introcular lenses

Date of registration: 06/04/2020 ^(mm/dd/yyyy)
Last approval date : 06/04/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of physical exercise under different levels of effort to prevent atherosclerosis and risk factors in elderly women

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation with ultrasound on the bedside in serious patients with COVID-19

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Effects of different physical activity programs on women's health

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of vitamin D3 supplementation on oxidative and inflammatory stress markers in overweight or obese workers

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of irritability and sensitization of health products, through the contact test.

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Mindfulness Training for Stress reduction in workers at a university in the interior of São Paulo

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Guided implant surgeries x Freehanded surgeries

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Improvement of quality of life after knee prosthesis

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

To wear wrist orthosis can cause compensation on shoulder movement

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Therapeutic Ultrasound associated with the application of copaiba and tea tree oil in the treatment of leg ulcers: a controlled and randomized clinical study

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Histomorphometric and immunohistochemical evaluation of beta-tricalcium phosphate of different particles dimensions in maxillary sinus floor elevation: a randomized clinical study

Date of registration: 06/03/2020 ^(mm/dd/yyyy)
Last approval date : 06/03/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Randomized, pragmatic, double-blind, placebo-controlled clinical study, evaluation of Hydroxychloroquine for prevention of hospitalizations and respiratory complications in outpatients with confirmed or probable diagnosis of COVID-19

Date of registration: 04/08/2020 ^(mm/dd/yyyy)
Last approval date : 06/02/2020 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Mechanical ventilator for use in patients with respiratory failure due to Covid-19 (VExCO)

Date of registration: 06/02/2020 ^(mm/dd/yyyy)
Last approval date : 06/02/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of laser therapy on orofacial muscles

Date of registration: 06/02/2020 ^(mm/dd/yyyy)
Last approval date : 06/02/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Botox study and facial Anesthetic Infiltration on the Tinnitus Intensity in Patients with Temporomandibular Disorders

Date of registration: 06/02/2020 ^(mm/dd/yyyy)
Last approval date : 06/02/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

04/01/2026

The Indo-Australian Biotech Bridge: Strategic Synergies in Clinical Trials

04/01/2026 | The Policy Edge

https://www.policyedge.in/p/the-indo-australian-biotech-bridge-strategic-synergies-in-clinical-trials

The Australian Trade and Investment Commission (Austrade) has highlighted a burgeoning strategic partnership at BioAsia 2026, driven by India’s AUD 236 billion biotech sector seeking Australia’s regulatory speed.

Indian innovators are increasingly utilising Australia’s Clinical Trial Notification (CTN) pathway, which allows trials to commence immediately after ethics approval, often within 6 to 12 weeks, compared to traditional 16-week timelines elsewhere. This "Fast-Track" access is coupled with a high degree of Data Governance; Australian Phase 1 data is widely accepted by the US FDA and European EMA.

While Australia provides rapid, high-quality early-phase data and significant R&D tax benefits, India offers the late-phase scale, massive patient populations, and cost-effective manufacturing necessary for global commercialisation.

Strategic Components of the Biotech Corridor

Regulatory Efficiency: Australia’s risk-based CTN system offers a competitive advantage for firms racing for "first-in-human" or "proof-of-concept" data.
Global Market Entry: Australian trial results act as a validated gateway for Indian firms targeting high-value markets in Boston, Paris, and beyond.
Complementary Strengths: The partnership creates a "Practical Pathway" where Australia handles early-phase precision and India manages development volume and mass production.
Manufacturing Synergy: Australian biotech firms are simultaneously looking to India to leverage its immense manufacturing capacity to bring Australian discoveries to the global market.

04/01/2026

IAVI announces the onset of first-in-human Phase 1 clinical trial of broadly neutralizing antibodies (bnAbs) to prevent HIV transmission

04/01/2026 | IAVI ( International AIDS Vaccine Initiative)

https://www.iavi.org/features/iavi-announces-first-in-humans-clinical-trial-of-hiv-antibodies/

The trial, run by the HIV Vaccines Trial Network (HVTN) and HIV Prevention Trials Network (HPTN), will evaluate the safety, dosing, pharmacokinetics, and ability of four bnAbs to neutralize HIV

IAVI is pleased to announce the use of its broadly neutralizing antibody (bnAb), ePGT121v1-LS, in a first-in-human, Phase 1 clinical trial that began on March 19, 2026. IAVI’s HIV bnAbs program is designed to develop efficacious antibodies that can prevent HIV transmission. The program is specifically geared for eventual use to prevent HIV transmission to infants during the post-natal period. With 120,000 children newly acquiring HIV in 2024 alone, and 50 percent of infant HIV acquisition taking place in the breastfeeding period, there is a clear need for additional prevention tools developed to protect this vulnerable population. The onset of this clinical trial is a significant step in examining whether a combination of broadly neutralizing antibodies could be this new tool. With robust safety and dose data collected through this study, which has only adult participants, IAVI’s team will have the necessary data to plan future studies in infants.

This clinical trial, HVTN 141/HPTN105, will use four antibodies that target different HIV receptors. Based on past studies, the antibodies together are expected to neutralize more strains of HIV than any antibody alone. IAVI’s antibody will be given by itself and together with two of the three additional antibodies, VRC07-523LS and PGDM1400LS. The fourth antibody, PGT121.414.LS, will be given by itself and in combination with these same two antibodies. Doses will be delivered by IV, under…

03/31/2026

Brazilian study shows improved memory in Alzheimer's patients treated with cannabis

03/30/2026 | Raphael Bezerra | Jornal Opção

https://www.jornalopcao.com.br/ultimas-noticias/estudo-brasileiro-aponta-melhora-na-memoria-em-pacientes-com-alzheimer-tratados-com-cannabis-808878/

A group of 13 Brazilian researchers led by Francisney Pinto Nascimento, PhD in pharmacology at the Federal University of Latin American Integration (Unila), identified cognitive improvement in Alzheimer’s patients treated with low-dose cannabis extracts. The results appear in two scientific publications—a 2022 report and a randomized clinical trial published in 2025—which point to positive effects on memory, with a safety profile considered favorable.

The research line investigates the use of cannabinoids as a therapeutic alternative for improving Alzheimer’s, a neurodegenerative condition that affects millions of people worldwide and for which there is still no cure. For biomedical scientist and researcher Isabela Carvalho Freitas, affiliated with the Federal University of Goiás (UFG), the observed effects can be explained by the interaction of cannabinoids with the endocannabinoid system, which is responsible for regulating functions such as mood, sleep, appetite, and stress response.

According to the expert, modulating this system may contribute to symptom management and improved quality of life in Alzheimer’s patients, particularly regarding behavioral symptoms, which still pose significant clinical challenges.

She also highlights the growing academic interest in the topic and notes that historical regulatory barriers have hindered the production of robust scientific evidence. “The lack of research restricts use, and the restriction hinders the advancement of research,” she states in an interview with Jornal…

03/31/2026

The Right to Health: Between Innovation and Regulation of Polylaminin

03/30/2026 | Maria Prevot and Franco Mauro Russo Brugioni | Migalhas.com

https://www.migalhas.com.br/depeso/452905/o-direito-a-saude-entre-a-inovacao-e-a-regulacao-da-polilaminina

Polylaminin, in initial trials, sparks legal debate over coverage of experimental treatments in the face of urgency and scientific uncertainty.

Reports have recently surfaced regarding a new substance, still in the testing phase, that could be used in an attempt to reverse paralysis resulting from spinal cord injury.

This substance is polylaminin, a derivative of laminin, developed through research at the Federal University of Rio de Janeiro (UFRJ) and currently funded for clinical trials. The development of this substance brings a topic in Health Law back to the center of the debate: when therapeutic hope gives rise to legal obligations for coverage before scientific consolidation. The case is emblematic because the news highlights that this is investigational technology, in the early stages of human testing, aimed at severe acute spinal cord injuries.

From a regulatory standpoint, the turning point is the transition from the experimental phase to authorized clinical research. In January 2026, Anvisa authorized a Phase 1 study to evaluate the safety of polylaminin in five patients with complete thoracic injuries. The Ministry of Health has signaled institutional interest in innovative technologies for the SUS. These developments do not imply automatic registration or incorporation, but they raise the level of seriousness of the treatment in the eyes of the judiciary, as they indicate risk management and monitoring of adverse events.

In this interim period—between research authorization and incorporation—the likelihood of judicial rulings increases. There is a concrete…

03/30/2026

1st WebRede will debate the effectiveness of the vaccine against Covid-19 in health professionals

03/30/2026 | Bio-Manguinhos

https://campusvirtual.fiocruz.br/portal/?q=noticia/97937

The Institute of Immunological Technology (Bio-Manguinhos/Fiocruz) promotes this second fair, March 30, at 2 p.m., in the first edition of WebRede: Effectiveness and safety of the vaccine against Covid-19 in health professionals and messenger RNA technology. The activity is carried out in partnership with the Fiocruz Clinical Research Network and kicks off a series of webinars scheduled for this year.

The event, promoted by the Department of Medical Affairs, Clinical Studies and Post-Registration Surveillance and the Desk of Technological Development Projects, will present the Rede de Estudos Observacionais (Covid-19 Network) and the results of Eixo 2 of the study, which supports the effectiveness and safety of Covid-19 vaccines, with focus Vaccines distributed by the National Immunization Program in health professionals, along with messenger RNA technology. You will have participated in the Bio-Manguinhos Technological Development Projects Desk and at the University Hospital of Brasília (HUB-UnB/Ebserh).

The webinar is intended for health professionals, researchers, postgraduates, managers, research participants and others interested in the subject. Registrations must be made on the Even3 platform. You will have transmission via Teams, with access to the Even 3 platform.